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Objective
The objective of this study was to evaluate the effect of intranasal corticosteroid versus
hypertonic saline irrigation on the nasalance scores in patients with vasomotor rhinitis (VMR).

Patients and methods

The study was conducted on 71 patients recruited from the Otolaryngology Department, Kasr
El‑Aini Hospital, Cairo University, with a history of nasal obstruction for at least 6 months, clinical
and endoscopic evidence of VMR, and negative skin prick test. The patients were subjected to
nasometric evaluation to obtain their nasalance scores before treatment. The patients were then
randomly classified into two groups: group A, which included 33 patients who were instructed
to apply mometasone furoate nasal spray two puffs in each nostril once per day for 3 months,
and group B, which included 38 patients who were instructed to apply hypertonic saline nasal
spray three times per day for 3 months. Patients of the two groups were re‑evaluated by means
of nasometry to assess the change in their nasalance scores after each treatment plan.

Results

The mean pretreatment nasometry score for group A was 34.55 ± 7.71, the minimum score was
18.7, and the maximum score was 48. The post‑treatment nasometry score for the same group
showed a mean of 46.44 ± 7.76 and ranged from a minimum of 29.9 to a maximum of 58.2.
The difference between the two scores was found to be statistically significant (P = 0.014). As
regards group B, the mean pretreatment nasometry score was 36.04 ± 7.36, the minimum score
was 17.4, and the maximum score was 47.3. The post‑treatment nasometry score for the same
group showed a mean of 45.57 ± 7.4 and ranged from a minimum of 29.3 to a maximum of 55.
The difference between the two scores was found to be statistically highly significant (P = 0.001).

Conclusion

It appears that intranasal hypertonic saline is highly effective in the treatment of VMR and
approaches the effect of intranasal corticosteroids.
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Introduction
Rhinitis is inflammation of the nasal lining characterized
by nasal congestion, rhinorrhea, sneezing, and/or
nasal itching [1]. Rhinitis is classified into allergic,
nonallergic, occupational, hormonal (pregnancy and
hypothyroidism), drug‑induced, and food‑related
subtypes [2]. Vasomotor rhinitis (VMR) is the most
common form of chronic nonallergic rhinitis (NAR).
Recent articles have noted that VMR may sometimes
be a ‘wastebasket diagnosis’. This is because VMR is
an idiopathic condition diagnosed in the absence
of infection, allergy, eosinophilia, hormonal
changes (such as pregnancy and hypothyroidism),
and exposure to drugs (oral contraceptives, estrogens,
angiotensin‑converting enzyme inhibitors, receptor
blockers, antihypertensives, aspirin, chlorpromazine,
NSAIDs, and topical nasal decongestants) [3,4].
Several hypotheses have been proposed for the
pathophysiology of VMR, such as autonomic
dysfunction and trauma [5].

It is not possible to distinguish between perennial
allergic rhinitis and NAR on the basis of symptoms
alone. VMR is more commonly associated with nasal
obstruction and postnasal drip. Allergic rhinitis is
more commonly associated with itching, redness,
clear rhinorrhea, and watery eyes. NAR affects a
disproportionate percentage of female population,
which may be the result of endocrinologic influences [6].
Intranasal steroids are usually prescribed for the
management of VMR. Although the efficacy and
safety of intranasal corticosteroids (INCs) are well
established for the management of allergic rhinitis,
rhinosinusitis, and nasal polyps, concerns remain among
some patients, caregivers, and healthcare providers
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that these agents may reach the systemic circulation in
sufficient concentrations to produce adverse effects [7].
These side effects include growth inhibition induced
by hypothalamus–pituitary–adrenal axis suppression,
decreased bone mineral density, myopathy, cataract,
glaucoma, hypertension, hyperglycemia, and thin or easily
bruised skin [8]. Nasal irrigations may be used for a variety
of conditions [9]. Their use is included in the management
of acute and chronic rhinosinusitis [10], allergic and NAR,
nonspecific nasal symptoms (including postnasal drip),
septal perforations, and the postoperative care of surgical
patients. The use of prescribed nasal medications can
be decreased as a result of nasal irrigations in some
circumstances due to the effect of nasal irrigations on
alleviating nasal symptoms [11]. Nasal irrigations have
been shown to be safe and side effects encountered are
minimal, such as local irritation, itching, burning, otalgia,
and pooling in sinuses with subsequent drainage [12].
This pooling, with delayed discharge in some head
positions, is most commonly seen in patients who have
undergone previous sinus surgery [11]. Various reports
suggest that hypertonic nasal irrigations are superior to
isotonic nasal irrigations [13].
Nasometry is a technique to measure the oral and
nasal components of nasalance. Nasalance is an
objective measure of the nasal component of speech
that is determined by the ratio of acoustic pressures
emitted from the nasal and oral cavities. The nasometer
provides a nasalance score based on the ratio of nasal
acoustic energy to total acoustic energy (oral and nasal).
Acceptable levels of agreement between the measure
provided by the nasometer (nasalance score) and the
auditory‑perceptual measure of hypernasality has been
demonstrated through numerous studies resulting in
the acceptance of nasometry for both use in the clinic
and laboratory [14,15].

Patients and methods
The current prospective study was conducted on
71 patients recruited from the Otolaryngology
Department, Kasr El‑Aini Hospital, Cairo University,
during the period from June 2014 to April 2016. The
study protocol was approved by the Local Ethical
Committees of Kasr El‑Aini Hospital, and all study
participants signed a written fully informed consent
form. The main complaint of all patients was nasal
obstruction. Other complaints included rhinorrhea,
sneezing, nasal itching, and smell disorder.
Every patient was subjected to detailed history taking,
complete general and otolaryngologic examination,
diagnostic nasal endoscopy, and skin prick test. The
main characteristic finding of the examination of these
patients was inferior turbinate hypertrophy (of varying
degrees). Other findings included swelling of the nasal
mucosa, wetting of the nasal cavity, and in some cases
prominent vessels along the nasal cavity floor. Patients
older than 18 years with a history of nasal obstruction
for at least 6 months, clinical and endoscopic evidence
of VMR, and negative skin prick test were included
in our study. The exclusion criteria were as follows: (a)
active upper respiratory tract infection throughout the
duration of the study; (b) history of nasal surgery; (c)
history of asthma; (d) nasal polypi masses or tumors; (e)
associated nasal septal deviation; (f ) history of topical
or systemic antiallergic treatment for at least 2 months
before enrollment in the study; and (g) pregnancy,
lactation, or use of contraceptive pills.

According to Wetmore [16], the nasal cavity can provide
as much as 50% of the total resistance to nasal airflow.
Nasal airway obstruction/resistance can be increased in
a variety of nasal conditions, including allergic rhinitis,
NAR, and rhinosinusitis. This is attributed to swelling
of nasal mucosa and hypertrophy of inferior turbinates.
In these conditions, the acoustic energy emitted
from the nose during speech evaluation by means
of nasometry is reduced, resulting in hyponasality.
Decreasing this nasal resistance (by medical or surgical
means) leads to an increase in the nasal component of
speech, which is reflected during nasometric study as
improvement in the nasalance scores.

The patients were subjected to nasometric evaluation
to obtain their nasalance scores before treatment using
the model 6200‑2 nasometer (Kay Elemetrics, New
Jersey, United States). Calibration, data recording,
and calculation of nasalance scores were carried
out according to the procedures described in the
nasometer’s instructional manual. The nasometer
is a computer‑based device that analyzes acoustic
energy that is emitted from the oral and the nasal
cavity during speech. It consists of two microphones
that are separated by a plate. The upper microphone
measures nasally emitted acoustic energy, and the lower
microphone measures the acoustic energy emitted from
the oral cavity. The participant is then asked to read
standard passages. While the participant is reading,
the microphone captures sound pressure levels, which
are emitted from the nasal and the oral cavity. These
data were analyzed using the attached computer and
presented graphically providing a nasalance score.

The current prospective study aimed to evaluate the
effect of intranasal corticosteroid versus hypertonic
saline irrigation on the nasalance scores in patients
with VMR.

The patients were then randomly classified into two
groups: group A, which included 33 patients who were
instructed to apply mometasone furoate nasal spray
two puffs in each nostril once per day for 3 months,
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and group B, which included 38 patients who were
instructed to apply hypertonic saline nasal spray three
times per day for 3 months. Patients of the two groups
were re‑evaluated by means of nasometry to assess the
change in their nasalance scores after each treatment
plan. Post‑treatment nasal scores were categorized
as follows: (a) normalized, if the score was 48.8 or
above; (b) partially improved, if the score increased but
did not reach normal value (48.8); and (c) resistant, if
the score was the same or decreased.
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Considering those patients who showed partial
improvement in group A, three of 13 (23.1%) showed at
least 50% improvement and the remaining 10 (76.9%)
improved by less than 50%. Considering those patients
who showed partial improvement in group B, two of
14 (14.3%) showed at least 50% improvement and
the remaining 12 (85.7%) improved by less than 50%.
The difference in the results of partial improvement
was not statistically significant (P = 0.64) (Table 1
and Figs. 1–3).

Statistical analysis

Microsoft Excel 2010 was used for data entry, and
the statistical package for the social sciences (SPSS
version 21 Chicago, USA, IBM Corporation) was used
for data analysis. Simple descriptive statistics (arithmetic
mean and SD) was used for summary of quantitative
data and frequencies were used for qualitative data.
Fisher’s exact test was used for categorical variables.
For metric variables, the unpaired t‑test was used for
variables that satisfied the normality assumption; the
Mann–Whitney test was used for those that did not.

Results
The study included 71 patients with symptoms
of nasal obstruction, with a mean age of 36 years,
(range 18–53 years) with a male‑to‑female ratio of 1.4:1.
The mean pretreatment nasometry score for group A
was 34.55 ± 7.71, the minimum score was 18.7, and
the maximum score was 48. The post‑treatment
nasometry score for the same group showed a
mean of 46.44 ± 7.76 and ranged from a minimum
of 29.9 to a maximum of 58.2. The difference
between the two scores was found to be statistically
significant (P = 0.014). As regards group B, the mean
pretreatment nasometry score was 36.04 ± 7.36, the
minimum score was 17.4, and the maximum was
47.3. The post‑treatment nasometry score for the
same group showed a mean of 45.57 ± 7.4 and ranged
from a minimum of 29.3 to a maximum of 55. The
difference between the two scores was found to be
statistically highly significant (P = 0.001).
Among the 33 patients who were treated with
mometasone furoate, 19 (57.6%) were normalized and
13 (39.4%) showed partial improvement, whereas only
one (3%) was resistant to treatment. For the 38 patients
who received hypertonic saline, 20 (52.6%) were
normalized, 14 (36.8%) showed partial improvement,
and four (10.5%) remained resistant to treatment. On
correlation of the differences in the post‑treatment
nasometric results between the two groups, it was not
statistically significant (P = 0.56).

Discussion
On analyzing the previous results and according to the
difference between the pretreatment and post‑treatment
nasometry scores between the two groups, 57.6 and
Table 1 The mean pretreatment and post treatment nasometry
scores as well as the therapy results of both groups
Group A
Pretreatment nasometry
score
Mean
Minimum
Maximum
Post‑treatment
nasometry score
Mean
Minimum
Maximum
P
0.014
Therapy results (n (%))
Normalized
Partial
improvement (n (%))
>50%
<50%
Resistant (n (%))

34.5
18.7
48

46.4
29.9
58.2
(significant)

19 (57.6)

Group B

P

36
17.4
47.3

45.6
29.3
55
0.001 (highly
significant)
20 (52.6)
0.56

3 (9.1)
10 (30.3)

2 (5.3)
12 (31.6)

1 (3)

4 (10.5)

Figure 1

Box plot showing the pretreatment nasometry score for both groups.
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Figure 2

Figure 3

Box plot showing the post treatment nasometry score for both groups.

Therapy results for both groups.

52.6% returned to normal nasometric score for those
treated with mometasone furoate and hypertonic saline,
respectively, in addition to those who showed partial
improvement but did not reach normal nasometric values.
This would high lighten the efficacy of future treatment
using either intranasal steroids or hypertonic saline with
nearly similar effect as shown by the non significant
difference of the therapy results between both groups.
Moreover, the improvement in the nasometry score of
both groups was statistically significant (P = 0.014 and
0.001 for groups A and B, respectively).

a statistically significant difference compared with the
pretreatment scores (P = 0.14).

Supporting our results, Cordray et al. [13] reported
clinical and statistical improvements in mean scores of
quality of life standard questionnaire among patients
treated with either intranasal corticosteroids or
hypertonic dead sea saline with difference between the
two groups.
The use of normal saline was shown to have some
benefit in the treatment of allergic rhinitis when it
is delivered with significant irrigating agent, and the
improvement of symptoms was related to mechanical
removal of allergens from the nasal mucosa [17].
Moreover, Cordray et al. [13] supported this finding
and they claimed that normal saline provides a clinical
benefit in some patients with allergic rhinitis.
Cordray et al. [13] reported the global anti‑inflammatory
effect of hypertonic saline in addition to the mechanical
irrigation of the nasal mucosa with positive effects on
the nasal mucosa and mucociliary clearance similar
to normal saline, and they concluded that intranasal
hypertonic saline is superior to plain saline solution
in the treatment of allergic rhinitis. According to our
results, we support this idea as the post‑treatment
nasometry scores greatly improved to reach a mean of
45.6 in the group treated with hypertonic saline with

As regards INCs treatment of VMR, it is clearly
proved with a large body of evidence that INCs are
highly effective in the treatment of VMR [17–20].
This is in agreement with our results as previously
mentioned. The mechanism of action of INCs in
VMR is by reducing the number of lymphocytes by
programmed cell death or apoptosis [21], inhibiting
T‑lymphocyte activation, preventing an increase in
interleukin‑4, 5 and local IgE [22,23], and inhibiting
eosinophil activation and interleukin‑2 production and
generation [24,25].

Conclusion
It appears that intranasal hypertonic saline is highly
effective in the treatment of VMR and approaches
the effect of INCs. Therefore, we recommend that the
dual use of hypertonic saline in addition to INCs may
have a superior effect to the sole use of either agent in
the treatment of VMR, particularly among patients
who are resistant to treatment with a single agent.
Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1 International Rhinitis Management Group. International consensus
report on the diagnosis and management of rhinitis. Allergy 1994;
49(Suppl):1–34.

Nasalance measures outcome in vasomotor rhinitis patients Fathy et al.
2 Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, BlessingMoore J, et al. Diagnosis and management of rhinitis: complete guidelines
of the Joint Task Force on Practice Parameters in Allergy, Asthma and
Immunology. Ann Allergy Asthma Immunol 1998; 81:478–518..
3 Smith TL. Vasomotor rhinitis is not a wastebasket diagnosis. Arch
Otolaryngol Head Neck Surg 2003; 129:584–587.
4 Corey JP. Vasomotor rhinitis should not be a wastebasket diagnosis. Arch
Otolaryngol Head Neck Surg 2003; 129:588–589.
5 D Lal, Jacquelynne PC. Vasomotor rhinitis update. Curr Opin Otolaryngol
Head Neck Surg 2004; 12:243–247.
6 Settipane RA, Lieberman P. Update on non‑allergic rhinitis. Ann Allergy
Asthma Immunol 2001; 86:494–507.
7 Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids.
J Investig Allergol Clin Immunol 2012; 22:1–12.
8 Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review
of safety and systemic effects. Drug Saf 2007; 30:317–326.
9 Papsin B, Tavish A. Saline nasal irrigation: its role as an adjunct treatment.
Can Fam Physician 2003; 49:168–273.
10 Lanza DC, Kennedy DW. Adult rhinosinusitis defined. Otolaryngol Head
Neck Surg 1997; 117:S1–S7.
11 Heatley DG, McConnell KE, Kille TL, Leverson GE. Nasal irrigation for
the alleviation of sinonasal symptoms. Otolaryngol Head Neck Surg 2001;
125:44–48.
12 Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review
of nasal irrigation. Laryngoscope 2000; 110:1189–1193.
13 Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic dead
sea saline spray and intanasal aqueous triamcinolone spray in seasonal
allergic rhinitis. ENT J 2005; 84:426–430.

55

16 Wetmore RF. Importance of maintaining normal nasal function in the cleft
palate patient. Cleft Palate J 1992; 29:498–506.
17 Ratner PH, van Bavel JH, Martin BG, Hampel FC Jr, Howland WC 3rd,
Rogenes PR, et al. A comparison of the efficacy of fluticasone propionate
aqueous nasal spray and loratadine alone and in combination, for the
treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47:118–125.
18 Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM.
Superiority of an intranasal corticosteroid compared with an oral antihistamine
in the as‑needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001;
161:2581–2587.
19 Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus
oral H1 receptor antagonists in allergic rhinitis: systematic review of
randomized controlled trials. BMJ 1998; 317:1624–1629.
20 Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of
beclomethasone dipropionate aqueous nasal spray, astemizole, and
the combination in the prophylactic treatment of ragweed pollen‑induced
rhinoconjunctivitis. J Allergy Clin Immunol 1989; 83:627–633.
21 Cohen JJ. Lymphocyte death induced by glucocorticoids. In: Schleimer RP,
Claman HN, Oronsky A, editor. Antiinflammatory steroid action: basic and
clinical aspects. San Diego: Academic Press; 1989. 110–131.
22 Masuyama K, Jacobson MR, Rak S, Meng Q, Sudderick RM, Kay AB,
et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells
expressing cytokine mRNA for interleukin‑4 in the nasal mucosa in
allergen‑induced rhinitis. Immunology 1994; 82:192–199.
23 Alvarado C, Reed C, Gleich T, Field E, Pobiner B, Wisniewski M.
Fluticasone propionate aqueous nasal spray reduces nasal eosinophils
and cytokine activity of patients with allergic rhinitis. J Allergy Clin Immunol
1995; 95: 193.

14 Dalston RM. The use of nasometry in the assessment and remediation
of velopharyngeal inadequacy. In: Bzoch KR, editor Communicative
disorders related to cleft lip and palate. Austin, TX: Pro‑ed; 2004. 161-191.

24 Schleimer RP. Glucocorticosteroids: their mechanism of action and use
in allergic diseases. In: Middleton E, Reed CE, Ellis EF, Adkinson NF,
Yunginger JW, editors. Allergy principles and practice. Washington, DC:
Mosby; 1988. 739–765.

15 Nandurkar A. Nasalance measures in Marathi consonant‑vowel‑consonant
syllables with pressure consonants produced by children with and without
cleft lip and palate. Cleft Palate Craniofac J 2002; 39:59–65.

25 Reed JC, Abidi AH, Alpers JD, Hoover RG, Robb RJ, Nowell PC. Effect
of cyclosporin A and dexamethasone on interleukin‑2 receptor gene
expression. J Immunol 1986; 137:150–154.

